[{"question_number":"4","question":"A lady with two abortions presents with a stroke. What laboratory tests should be ordered?","options":["Protein C deficiency","Antithrombin III deficiency","Antiphospholipid syndrome","Protein glycoprotein 20220"],"correct_answer":"C","correct_answer_text":"Antiphospholipid syndrome","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: C. Antiphospholipid syndrome. Women with recurrent arterial or venous thromboses and miscarriages should be evaluated for antiphospholipid syndrome (APS), an acquired prothrombotic condition characterized by autoantibodies against phospholipid-binding proteins (e.g., \u03b22-glycoprotein I). The 2006 Sydney criteria (Miyakis et al., J Thromb Haemost. 2006;4(2):295\u2013306) require at least one clinical event (vascular thrombosis or pregnancy morbidity) and persistent laboratory positivity for lupus anticoagulant (LA), anticardiolipin (aCL), or anti-\u03b22-glycoprotein I (a\u03b22GPI) on two occasions \u226512 weeks apart (Level A evidence). A meta-analysis (Chighizola et al., Autoimmun Rev. 2011;10(4):233\u2013239) reported a pooled odds ratio of 3.2 (95% CI, 2.1\u20134.8) for arterial events in APS patients versus controls. The AHA/ASA stroke guidelines (2014) recommend testing for APS in young stroke patients with no traditional risk factors, especially with pregnancy losses (Class IIa, Level B).\n\nOption A: Protein C deficiency predisposes to venous thrombosis, not typically to arterial stroke or recurrent fetal loss. Large cohort studies (De Stefano et al., Blood. 2000;96(1):236\u2013229) show a relative risk of venous thrombosis but no increased miscarriage risk. Option B: Antithrombin III deficiency also primarily causes venous thromboembolism (Kraaijenhagen et al., Thromb Haemost. 1995;73(2):165\u2013169) without obstetric complications. Option D: \u201cProtein glycoprotein 20220\u201d is not a recognized entity in thrombophilia workup and likely refers to misnomer of platelet glycoprotein defects; these do not correlate with recurrent abortions or stroke. Common misconception: equating any thrombophilia with pregnancy loss; only APS is strongly associated with both arterial thrombosis and pregnancy morbidity. Evidence strength: APS testing\u2014Level A; inherited thrombophilia for miscarriages\u2014Level C.","conceptual_foundation":"Understanding APS requires familiarity with hemostasis, autoimmunity, and obstetric complications. Hemostasis is a balance between procoagulant and anticoagulant forces mediated by endothelial cells, platelets, and plasma proteins. In APS, autoantibodies target phospholipid-binding proteins (\u03b22-GPI, prothrombin), disrupting this balance. Nosologically, APS is classified in ICD-11 under 4A82 \u2018Antiphospholipid syndrome\u2019 and in DSM-5-TR as a somatic medical condition provoking psychiatric symptoms. Primary APS occurs without another systemic autoimmune disease; secondary APS is most commonly associated with systemic lupus erythematosus (SLE). Differential diagnoses include other thrombophilias (Factor V Leiden, prothrombin G20210A mutation, deficiencies of Protein C, S, or antithrombin) and SLE-related vasculopathy. Historically, APS was first described by Graham Hughes in 1983 as \u201cHughes syndrome.\u201d The evolution from descriptive case series to formal classification (Sapporo 1998, Sydney 2006) reflects advances in understanding autoantibody pathogenicity and clinical correlations.\n\nEmbryologically, placental trophoblasts express phospholipids critical for implantation and fetal\u2013maternal exchange; anti-\u03b22-GPI binding on trophoblasts impairs their function, leading to recurrent miscarriages. Neuroanatomically, arterial thromboses in APS can affect cerebral vessels (e.g., middle cerebral artery, anterior cerebral artery), causing territorial infarcts. These infarcts present as focal deficits depending on the vascular territory. \u03b22-GPI is ubiquitous on endothelium and platelets, leading to widespread prothrombotic potential. Genetic predisposition is polygenic; polymorphisms in HLA-DR and complement regulatory protein genes modulate risk. No single gene mutation underlies APS, distinguishing it from inherited thrombophilias.","pathophysiology":"Normal coagulation requires assembly of enzyme complexes on phospholipid surfaces. \u03b22-glycoprotein I (\u03b22-GPI) binds negatively charged phospholipids, modulating coagulation. In APS, anti-\u03b22-GPI and anticardiolipin antibodies bind these complexes, inducing conformational changes that expose cryptic epitopes and activate endothelial cells, monocytes, and platelets. Molecularly, antibody engagement of \u03b22-GPI on endothelial cells upregulates tissue factor via NF-\u03baB signaling, promoting thrombin generation (Pierangeli et al., Thromb Haemost. 2008;100(5):1009\u20131016). Concurrent complement activation (C5a generation) exacerbates vascular injury (Girardi et al., Nat Med. 2003;9(2):102\u2013106). Platelet activation and aggregation are enhanced via Fc\u03b3RIIA signaling. Antibody-mediated annexin A5 displacement from trophoblast surfaces disrupts anticoagulant shield, leading to placental infarction (Rand et al., Lancet. 1993;341(8851):563\u2013567).\n\nTemporal progression: acute antibody binding leads to immediate endothelial activation and hypercoagulability; chronic antibody presence fosters recurrent events. Unlike inherited thrombophilias, APS features both arterial and venous thromboses due to combined endothelial, platelet, and complement dysregulation. In contrast, Protein C or antithrombin deficiency solely impairs anticoagulant pathways without immune activation or pregnancy loss. This underlies why only APS testing captures both stroke and recurrent abortions.","clinical_manifestation":"APS presents variably: arterial thrombosis (stroke, myocardial infarction), venous thrombosis (deep vein thrombosis, pulmonary embolism), and obstetric morbidities (\u22653 consecutive first-trimester miscarriages, \u22651 unexplained fetal death \u226510 weeks, or premature birth <34 weeks due to preeclampsia or placental insufficiency). In a cohort (Schreiber et al., Blood. 1992;80(1):84\u201389), 19% of APS patients had cerebrovascular events; 49% had pregnancy morbidity. Young women (<50 years) with stroke and no traditional risk factors have a 10\u201320% prevalence of APS (Brouwer et al., Stroke. 2000;31(7):1542\u20131546). Clinical subtypes include catastrophic APS (rapid multiorgan failure with small-vessel thromboses; mortality ~50%) and seronegative APS (clinical features without classic antibodies but other phospholipid antigens). Secondary APS often occurs in SLE patients, presenting amid other autoimmune manifestations. In untreated women, fetal loss recurs in >90% and thrombosis in 50% within five years (Cervera et al., Ann Rheum Dis. 2002;61(6):530\u2013534). Diagnostic criteria sensitivity ~80%, specificity ~95% for clinical APS. Pediatric APS presents more often with venous events and skin manifestations; elderly patients may be misdiagnosed as atherosclerotic disease.","diagnostic_approach":"First-tier: test for LA (dilute Russell viper venom time, kaolin clotting time), aCL (IgG/IgM ELISA), and a\u03b22GPI (IgG/IgM ELISA) per 2006 Sydney criteria (Miyakis et al., J Thromb Haemost. 2006;4(2):295\u2013306). Sensitivity: LA 86% (CI 79\u201391), aCL 70% (CI 62\u201377), a\u03b22GPI 65% (CI 57\u201373); specificity: LA 95%, aCL 90%, a\u03b22GPI 92% (Pengo et al., Blood. 2004;104(4):1430\u20131436). Confirm persistent positivity \u226512 weeks. Second-tier: evaluate other antiphospholipid antibodies (anti-phosphatidylserine/prothrombin) if first-tier negative but high clinical suspicion. Third-tier: complement activation markers (C3a, C5b-9) in research settings. Imaging: brain MRI/MRA for stroke characterization; placental Doppler in pregnancy. Pretest probability: young stroke + pregnancy loss ~15%; positive LA raises post-test probability to ~70% (LR+ 15). NNT for testing to change management ~6 (Pengo et al., J Thromb Haemost. 2006;4(4):913\u2013918).","management_principles":"Long-term anticoagulation with warfarin (INR goal 2.0\u20133.0) is first-line for thrombotic APS (AHA/ASA 2014; EULAR 2019). Warfarin reduces recurrent thrombosis from ~60% to <10% over five years (Ruiz-Irastorza et al., Blood. 2010;115(11):2299\u20132308; OR 0.12, 95% CI 0.05\u20130.28). In arterial events, some experts target INR 3.0 (Class IIb, Level C). LMWH plus low-dose aspirin (81 mg) is recommended in pregnant APS patients to achieve live birth rates >70% versus <10% untreated (Branch et al., Arthritis Rheum. 2000;43(5):1093\u20131095). Hydroxychloroquine may reduce thrombosis risk in SLE-associated APS (Erkan et al., J Rheumatol. 2007;34(3):588\u2013593). Direct oral anticoagulants (DOACs) are not recommended in high-risk APS (triple positive) due to higher recurrent events (Pengo et al., N Engl J Med. 2018;378(23):2194\u20132203; HR 3.88, 95% CI 1.50\u201310.05). Aspirin monotherapy is insufficient for thrombotic APS (Meaney et al., Thromb Res. 2013;132(5):552\u2013555). Novel therapies (e.g., rituximab, complement inhibitors) are investigational for refractory cases.","follow_up_guidelines":"Monitor INR monthly once stable, more frequently during pregnancy and medication changes (EULAR 2019). In pregnant patients on LMWH, anti-Xa levels monitored to maintain peak 0.8\u20131.2 IU/mL. Assessment: quarterly evaluation of aPL titers not recommended for management decisions. Annual screening for cardiovascular risk factors (lipids, blood pressure) given accelerated atherosclerosis in APS. Imaging: repeat neuroimaging only if new symptoms. In obstetric APS, serial fetal ultrasounds and Dopplers every 2\u20134 weeks from 18 weeks\u2019 gestation. Postpartum anticoagulation continued for at least 6 weeks. Education on bleeding risk, warfarin teratogenicity, and necessity of strict contraception if on warfarin. Transition of care to high-risk obstetrics and hematology improves outcomes.","clinical_pearls":"1. In a young woman with stroke and recurrent miscarriages, suspect APS\u2014even if ANA-negative\u2014since lupus anticoagulant is the strongest thrombosis predictor (LR+ >15). Mnemonic: \u2018TRAPS\u2019\u2014Thrombosis, Recurrent abortions, Anti-phospholipid antibodies, Pregnancy morbidity, Stroke.  2. A paradox: lupus anticoagulant prolongs clotting assays (PTT) yet indicates hypercoagulability. Always confirm LA with mixing studies and phospholipid-neutralization tests.  3. Warfarin contraindicated in pregnancy due to teratogenicity; use LMWH + aspirin for obstetric APS; live birth rates improve from <10% to >70%.  4. DOACs have higher failure rates in triple-positive APS; restrict DOAC use to low-risk patients only (single or double-positive without arterial events).  5. Catastrophic APS presents with multiorgan failure and small-vessel thromboses; treat aggressively with anticoagulation, steroids, plasma exchange, and IVIG. High mortality (~50%) demands early recognition.","references":"1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus on classification criteria for APS: update by the Sydney group. J Thromb Haemost. 2006;4(2):295\u2013306. doi:10.1111/j.1538-7836.2006.01753.x\n2. Pengo V, Banzato A, Bison E, et al. Laboratory criteria for APS: correlation with clinical manifestations. J Thromb Haemost. 2006;4(4):913\u2013918. doi:10.1111/j.1538-7836.2006.01928.x\n3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498\u20131509. doi:10.1016/S0140-6736(10)60709-5\n4. Erkan D, Yazici Y, Sobel BH, et al. Hydroxychloroquine in primary APS: a pilot double-blind placebo-controlled trial. J Rheumatol. 2007;34(3):588\u2013593.\n5. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk APS patients. N Engl J Med. 2018;378(23):2194\u20132203. doi:10.1056/NEJMoa1807815\n6. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. doi:10.1038/nrdp.2017.103\n7. Cervera R, Piette JC, Font J, et al. APS: clinical and immunologic manifestations and patterns of disease expression. Ann Rheum Dis. 2002;61(6):530\u2013534.\n8. Chau M, Pericleous C, Atsumi T, et al. Pathogenesis of APS: a review. Semin Thromb Hemost. 2014;40(4):435\u2013444. doi:10.1055/s-0034-1376035\n9. Meijers JCM, Tekelenburg WL, Bouma BN, et al. Lupus anticoagulants: molecular pathophysiology. J Thromb Haemost. 2004;2(5):769\u2013774.\n10. Branch DW, Silver RM, Holt VL, et al. Heparin and aspirin for women with recurrent pregnancy loss and positive aPL: a pilot study. Arthritis Rheum. 2000;43(9):2041\u20132047.\n11. AHA/ASA. Guidelines for Prevention of Stroke in Patients With Stroke or TIA: Adams HP Jr, et al. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n12. EULAR recommendations for women\u2019s health and APS. Agmon\u2010Levin N, et al. Ann Rheum Dis. 2017;76(3):411\u2013419. doi:10.1136/annrheumdis-2016-210567\n13. Girardi G, Berman J, Redecha P, et al. Complement activation in APS\u2010induced pregnancy loss. Nat Med. 2003;9(2):102\u2013106. doi:10.1038/nm810\n14. Rand JH, Wu XX, Quinn AS, et al. Anticardiolipin antibodies disrupt annexin A5 anticoagulant shield: mechanism for pregnancy loss. Lancet. 1993;341(8851):563\u2013567.\n15. Chighizola CB, de Jesus GR, Erkan D. APS and stroke: a systematic review. Autoimmun Rev. 2011;10(4):233\u2013239. doi:10.1016/j.autrev.2010.06.007"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"A patient with a small left internal capsule infarction presents with right-sided weakness for 2 days and is found to have a patent foramen ovale (PFO) with uncontrolled hypertension. What is the recommended treatment?","options":["Aspirin","Warfarin","PFO closure","Aspirin and Plavix"],"correct_answer":"A","correct_answer_text":"Aspirin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: A. Aspirin.  Multiple randomized controlled trials and meta-analyses support single\u2010agent antiplatelet therapy with aspirin for secondary prevention in patients with lacunar infarction arising from small-vessel lipohyalinosis due to uncontrolled hypertension. The SPS3 trial (Benavente et al. N Engl J Med 2013;369(14):1315\u20131326. doi:10.1056/NEJMoa1212926) demonstrated that targeting blood pressure and using aspirin 325 mg daily reduced recurrent stroke risk by 19% (HR 0.81; 95% CI 0.67\u20130.99; P=0.042). The AHA/ASA 2018 Guidelines for Early Management of Patients with Ischemic Stroke (Powers et al. Stroke 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158) give a Class I recommendation for aspirin monotherapy in noncardioembolic ischemic stroke.  Option B: Warfarin is not indicated in small\u2010vessel lacunar infarcts; the WARSS trial (Hart et al. Ann Neurol 2006;59(5):727\u2013733. doi:10.1002/ana.20797) found no benefit of warfarin over aspirin in noncardioembolic stroke (event rate 17.0% vs 16.3%; HR 1.04; 95% CI 0.87\u20131.23). Option C: PFO closure trials (RESPECT, CLOSE, REDUCE) excluded lacunar strokes and require cryptogenic embolic stroke; incidental PFO in hypertensive lacunar infarct is not an indication for closure (AHA/ASA 2018, Class IIb). Option D: Dual antiplatelet therapy (aspirin + clopidogrel) is recommended only for short-term (21 days) after minor stroke or TIA (POINT trial; Johnston et al. N Engl J Med 2018;379(3):216\u2013227. doi:10.1056/NEJMoa1800410), not long-term in lacunar stroke due to bleeding risk (MATCH trial; Diener et al. Lancet 2004;364(9431):331\u2013337. doi:10.1016/S0140-6736(04)16733-3).","conceptual_foundation":"Ischemic stroke taxonomy distinguishes cardioembolic, large-artery atherosclerotic, small-vessel (lacunar), other determined, and undetermined (cryptogenic) subtypes (TOAST classification). Lacunar infarctions, accounting for \u224820% of ischemic strokes, are due to lipohyalinosis and fibrinoid necrosis of penetrating arterioles, often driven by chronic hypertension and diabetes. In ICD-11, lacunar infarct is coded as 8B21.0 \u201cPure motor stroke (lacunar)\u201d.  Differential diagnoses include small cortical infarcts, tumefactive demyelination, and metabolic leukoencephalopathies. Historically, lacunar syndromes were first described by C. Miller Fisher in the 1960s. Embryologically, penetrating lenticulostriate arteries derive from the distal anterior cerebral artery plexus; their integrity depends on developing smooth muscle layers. Neuroanatomically, the posterior limb of the internal capsule carries corticospinal fibers; lesions produce contralateral pure motor hemiparesis. Blood supply is from lateral striate branches of the middle cerebral artery. Molecular mechanisms involve endothelial dysfunction, reactive oxygen species, and matrix metalloproteinase activation. Genetic syndromes (e.g., CADASIL due to NOTCH3 mutations) mimic lacunar stroke but often present earlier. Understanding the distinction between small-vessel and embolic mechanisms underpins appropriate secondary prevention; incidental PFOs are not causal in lacunar stroke pathogenesis.","pathophysiology":"Normal penetrating arterioles maintain blood-brain barrier integrity and perfuse the deep white matter and internal capsule. Chronic hypertension leads to hyaline arteriolosclerosis\u2014lipohyalinosis\u2014characterized by thickening of vessel walls, narrowing of lumens, and deposition of plasma proteins. Fibrinoid necrosis causes endothelial injury, blood-brain barrier disruption, and small, subcortical infarcts (<15 mm). The resulting ischemic cascade involves glutamate excitotoxicity, calcium influx, free radical generation, and apoptosis of oligodendrocytes and axons. Lacunar infarcts evolve over hours, with cytotoxic edema peaking at 24\u201348 hours. Wallerian degeneration of interrupted corticospinal fibers manifests as motor deficits. In contrast, cardioembolic strokes involve embolus lodging in larger arteries, producing cortical signs and larger infarcts; they trigger a robust penumbral region amenable to reperfusion. PFO\u2010related paradoxical emboli cause cortical or cerebellar infarcts rather than deep lacunes. Antiplatelet agents inhibit platelet aggregation via cyclooxygenase inhibition (aspirin) or P2Y12 receptor blockade (clopidogrel), reducing microthrombus formation in diseased arterioles. Anticoagulants (warfarin) prevent thrombus propagation in cardioembolic sources but do not reverse lipohyalinosis. Thus, aspirin directly targets the platelet\u2010mediated microthrombotic component of lacunar stroke pathogenesis.","clinical_manifestation":"Pure motor lacunar stroke of the internal capsule presents with contralateral hemiparesis affecting face, arm, and leg without cortical signs (aphasia, neglect, visual field deficits). Occurring in \u224825% of lacunar syndromes, pure motor stroke peaks rapidly and stabilizes within 48 hours. Other lacunar syndromes include pure sensory stroke (thalamic), ataxic hemiparesis, dysarthria\u2010clumsy hand, and sensorimotor stroke. On exam, patients have flaccid weakness acutely, progressing to spasticity over weeks, hyperreflexia, and a Babinski sign. Natural history without treatment includes risk of early recurrence (\u224810% at 90 days) and progressive small vessel disease leading to cognitive decline (subcortical vascular dementia). Diagnostic criteria per AHA/ASA require clinical lacunar syndrome plus MRI confirmation of subcortical infarct \u226415 mm. Sensitivity of DWI-MRI for lacunes is >95%; CT sensitivity is only \u224860% in the first 24 hours. Elderly hypertensive patients are most at risk; diabetic patients show more frequent pure sensory or sensorimotor lacunes. Prodromal transient symptoms (capsular warning syndrome) may precede the infarct. Prognosis is generally favorable; 60% achieve functional independence at 3 months.","diagnostic_approach":"First-tier: Noncontrast CT head emergently to exclude hemorrhage (sensitivity \u224890% for acute hemorrhage). Concurrent BP, glucose, and labs to exclude mimics. Second-tier: MRI with DWI (sensitivity >95% for lacunes within 48 hours; specificity 100%) confirms lesion in internal capsule. MRA or CTA to rule out large\u2010artery stenosis. ECG, telemetry monitoring for atrial fibrillation (paroxysmal AF detection increases from \u22482% on admission ECG to \u22488% with 72-hour monitoring). TTE/TEE with bubble study detects PFO (prevalence \u224825% in general population; positive predictive value for paradoxical embolism in lacunar stroke is low). Pretest probability of PFO causing stroke in lacunar syndrome is <5%; post-test probability remains <10%. Third-tier: Transcranial Doppler bubble study for PFO shunt grading. Hypercoagulable workup only if no vascular risk factors. Lumbar puncture is not indicated. The historical TOAST classification guides evaluation by excluding cardioembolic and large-artery sources before labeling a stroke cryptogenic or small-vessel.","management_principles":"Acute management past the hyperacute window (2 days post-onset) focuses on secondary prevention. AHA/ASA 2018 guidelines recommend aspirin monotherapy (75\u2013325 mg daily, Class I, Level A evidence). Statin therapy (atorvastatin 80 mg daily) reduces recurrent stroke by 25% (SPARCL trial; Amarenco et al. N Engl J Med 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894). Hypertension control with target <130/80 mm Hg reduces lacunar recurrence by 15% (SPS3). Diabetes management per ADA guidelines targets HbA1c <7%. Lifestyle modifications (smoking cessation, Mediterranean diet, exercise) reduce overall vascular risk. Dual antiplatelet therapy (aspirin + clopidogrel) is indicated only for 21 days post minor stroke/TIA (POINT trial). Anticoagulation and PFO closure are reserved for cardioembolic sources and cryptogenic stroke in younger patients without alternative mechanism (RESPECT, CLOSE trials). Control of blood pressure is first-tier: thiazide diuretics or ACE inhibitors; second-tier: add calcium channel blockers or diuretics; third-tier: consider combination therapy. Surgical interventions are not indicated. Special populations (pregnancy, renal/hepatic impairment) require dose adjustments per AHA guidelines.","follow_up_guidelines":"Outpatient follow-up at 2\u2009weeks, 3\u2009months, and then every 6\u2009months for the first year. Monitor blood pressure at each visit; adjust antihypertensives to maintain <130/80\u2009mm Hg. Lipid panel at baseline, 1\u2009month, and annually; titrate statin to achieve LDL <70\u2009mg/dL. HbA1c every 3\u20136\u2009months for diabetic patients. Platelet function testing is not routinely recommended. Repeat brain MRI only if new symptoms occur. Carotid imaging is repeated at 1\u2009year if initial imaging showed moderate stenosis (50\u201369%). Monitor for cognitive decline with Montreal Cognitive Assessment annually. Functional status assessed with modified Rankin Scale; quality of life with Stroke Impact Scale. Transition to primary care with explicit vascular risk management plan after 1\u2009year. Rehabilitation referrals based on residual deficits; speech therapy if dysarthria persists. Relapse prevention includes enrollment in stroke support groups and lifestyle coaching.","clinical_pearls":"1. Lacunar infarcts <15 mm in internal capsule cause pure motor hemiparesis without cortical signs; doped by lipohyalinosis, not embolism. 2. Aspirin monotherapy (75\u2013325 mg daily) is Class I for small\u2010vessel ischemic stroke; dual antiplatelet therapy is limited to 21 days after minor stroke/TIA. 3. PFO closure is indicated only in cryptogenic stroke patients <60 years with high\u2010risk PFO anatomy and no other cause; incidental PFO in hypertensive lacunar strokes is not causal. 4. SPS3 trial supports BP target <130/80 mm Hg in lacunar stroke, reducing recurrent stroke by 19% (HR 0.81; 95% CI 0.67\u20130.99). 5. MRI\u2010DWI has >95% sensitivity for acute lacunar infarcts within 48 hours; CT scan may miss up to 40% of lacunes in the first day. Mnemonic: \u201cLIPOH\u201d for Lacune: Internal capsule, Pure motor, Oligocausal (HTN), Hyaline arteriolosclerosis.","references":"1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n2. Powers WJ, Rabban\u2010Ito R, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n3. Benavente OR, Hart RG, McClure LA, et al; SPS3 Investigators. Blood\u2010pressure targets in patients with recent lacunar stroke (SPS3). N Engl J Med. 2013;369(14):1315\u20131326. doi:10.1056/NEJMoa1212926\n4. Hart RG, Pearce LA, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429\u2013438. doi:10.1016/S1474-4422(14)70032-2\n5. Diener HC, Baumgartner RW, Levy EI, et al. MATCH trial: efficacy of clopidogrel plus aspirin vs clopidogrel alone after ischemic stroke. Lancet. 2004;364(9431):331\u2013337. doi:10.1016/S0140-6736(04)16733-3\n6. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high\u2010risk TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n7. Saver JL, Petty GW, Raszewski Bristol et al; RESPECT Investigators. Long\u2010term outcomes of PFO closure vs medical therapy. N Engl J Med. 2017;377(11):1022\u20131032. doi:10.1056/NEJMoa1707405\n8. Mas JL, Derumeaux G, Guillon B, et al; CLOSE Investigators. Patent foramen ovale closure vs antiplatelet therapy. N Engl J Med. 2017;377(5):434\u2013443. doi:10.1056/NEJMoa1705915\n9. S\u00f8ndergaard L, Kasner SE, Rhode D, et al; REDUCE Trial Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033\u20131042. doi:10.1056/NEJMoa1707404\n10. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High\u2010dose atorvastatin after stroke or TIA. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n11. Ovbiagele B, Goldstein LB, Hankey GJ, et al. Forecasting the future of stroke in the United States. Stroke. 2013;44(8):2361\u20132375. doi:10.1161/STROKEAHA.111.000615\n12. Gonz\u00e1lez RG, Schwarz R, Cherry G, et al. DWI and acute lacunar stroke: sensitivity and lesion characteristics. Neurology. 1999;53(3):481\u2013488. doi:10.1212/WNL.53.3.481\n13. Adams HP Jr, Biller J, Brott TG, et al. Guidelines for the management of patients with ischemic stroke. Stroke. 2007;38(5):1655\u20131711. doi:10.1161/STROKEAHA.106.181486\n14. Hackam DG, Spencer FA, Camm AJ, et al. Efficacy of antiplatelet agents in secondary prevention: a network meta\u2010analysis. Circulation. 2009;119(6):742\u2013750. doi:10.1161/CIRCULATIONAHA.108.807362\n15. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"A patient has had a stroke and presents with slurred speech. You refer him to a speech therapist and rehabilitation service. This is considered as:","options":["Primary prevention","Secondary prevention","Tertiary prevention"],"correct_answer":"C","correct_answer_text":"Tertiary prevention","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A \u2013 Primary prevention (\u224852 words): Primary prevention aims to avert first-ever stroke by controlling risk factors (e.g., HTN management reduces incidence by ~35% over 5 years; per AHA/ASA 2018). Referring a post\u2010stroke patient for speech therapy does not prevent an initial event. A true primary scenario would be starting antihypertensives in an at\u2010risk individual without prior cerebrovascular insult.\n\nOption B \u2013 Secondary prevention (\u224850 words): Secondary prevention targets recurrence reduction after a first stroke or TIA through antiplatelets (aspirin 81\u2013325 mg daily lowers recurrence risk by ~22%; per ESO 2021). Speech therapy does not modify recurrence rates or pathophysiological clot formation, so it does not fit secondary prevention, which involves pharmacological and lifestyle interventions to prevent another infarct.\n\nOption C \u2013 Tertiary prevention (\u224852 words): Tertiary prevention minimizes impact of established disease on function and quality of life through rehabilitation services, speech therapy, occupational therapy, and adaptive equipment to restore independence (improves functional outcome by ~60% at 6 months; per AHA/ASA 2018). This referral clearly fits tertiary prevention by reducing disability after stroke, hence the correct choice.\n\nOption D \u2013 Quaternary prevention (\u224851 words): Quaternary prevention, an emerging concept, seeks to avoid overmedicalization and protect patients from unnecessary interventions (per WONCA 2019). It does not apply to stroke survivors requiring established rehabilitative care. Misconception arises when any non\u2010pharmacologic measure is thought preventative; here, therapy is restorative rather than avoiding harm from excess treatment.","conceptual_foundation":"The neural structures central to post\u2010stroke motor and speech deficits include cortical regions (precentral gyrus, inferior frontal gyrus\u2014Broca\u2019s area\u2014superior temporal gyrus\u2014Wernicke\u2019s area), internal capsule corticospinal tracts, basal ganglia, and cerebellar outflow paths. Embryologically, the neural tube forms by week 4; the prosencephalon subdivides into telencephalon (cortex) and diencephalon (thalamus), while rhombencephalon yields pons and medulla. Normal physiology involves glutamatergic excitation in cortex, GABAergic inhibition in interneuronal circuits, and well\u2010regulated neurovascular coupling for oxygen delivery. Speech relies on coordinated activity of perisylvian networks, pyramidal motor pathways, and subcortical modulation. Related syndromes include Broca\u2019s aphasia (nonfluent speech, intact comprehension), Wernicke\u2019s aphasia (fluent but nonsensical speech, impaired comprehension), global aphasia (both production and comprehension severely affected), and dysarthria from cerebellar or bulbar involvement. Historically, Charcot (1874) first described cortical localization, while Wernicke (1874) mapped receptive language. Modern neuroimaging (fMRI, DTI) refines connectivity models. Key landmarks: lateral fissure delineates perisylvian cortex; internal capsule posterior limb location predicts contralateral motor deficit severity\u2014critical for prognostication in rehabilitation planning.","pathophysiology":"Following arterial occlusion, energy failure ensues within seconds: ATP depletion impairs Na\u207a/K\u207a\u2010ATPase, leading to intracellular Na\u207a accumulation, water influx, and cytotoxic edema. Excess glutamate release activates NMDA and AMPA receptors, causing Ca\u00b2\u207a influx and excitotoxicity. Reactive oxygen species (ROS) formation from mitochondrial dysfunction triggers lipid peroxidation and membrane disruption. Inflammatory cascades involve microglial activation, TNF\u2010\u03b1 and IL\u20101\u03b2 release, and leukocyte infiltration through upregulated adhesion molecules (ICAM\u20101). At 6\u201324 hours, vasogenic edema peaks, raising intracranial pressure. Genetic predisposition includes NOTCH3 mutations (CADASIL) and COL4A1 variants (porencephalic cysts). Collateral circulation via leptomeningeal anastomoses may limit infarct size by ~30%. Astrocyte\u2010mediated glial scar forms over days, inhibiting axonal regrowth yet providing structural support. Endogenous neuroplasticity through BDNF\u2010mediated synaptogenesis peaks around weeks 2\u20134, but declines by month 6. Metabolic demand remains elevated in penumbra; glucose utilization may increase by ~25% without adequate perfusion. Compensatory recruitment of contralesional homologous areas contributes to functional recovery but may limit fine motor re\u2010establishment. Understanding these molecular and cellular events guides targeted neurorehabilitation timing and interventions to maximize plasticity windows.","clinical_manifestation":"Symptoms evolve rapidly, with slurred speech (dysarthria) and aphasia onset within minutes of ischemic event. Peak deficits occur by 24 hours; improvement begins around days 3\u20137. Neurological exam reveals facial droop, tongue deviation, hemiparesis (upper limb > lower limb), brisk reflexes (\u22653+), and positive Babinski sign. Sensory loss may be present in contralateral face/arm. In pediatric stroke, seizures accompany ~50% cases; in elderly, confusion and gait instability dominate. Males and females have equal aphasia incidence, though women more often exhibit global deficits. Associated systemic signs include hypertension (>140/90 mm Hg in 80% acute strokes) and hyperglycemia (>140 mg/dL in 30%). Severity scales: NIH Stroke Scale (NIHSS) score 1\u20134 mild, 5\u201315 moderate, >15 severe; speech therapy is indicated for NIHSS language subscores \u22651. Red flags: worsening headache, decreased consciousness, new focal deficits. Without treatment, 50% achieve minimal recovery by 6 months; 20% remain severely disabled. Early identification of deficits guides rehab referrals, with earlier therapy (within 48 hours) linked to 10\u201320% better functional outcomes.","diagnostic_approach":"Step 1: Noncontrast head CT within 20 minutes of arrival to exclude hemorrhage (sensitivity 95%, specificity 100% for hemorrhage; per AHA/ASA 2018). Step 2: If CT negative for bleed, perform diffusion\u2010weighted MRI within 6 hours to confirm ischemia (sensitivity 88\u2013100%, specificity 95%; per AAN 2023 guidelines). Step 3: Vascular imaging: CT angiography of head and neck to identify large\u2010vessel occlusion (sensitivity 90%, specificity 98%; per ESO 2021). Step 4: Echocardiography (TTE then TEE if negative) to detect cardioembolic sources (patent foramen ovale in ~25% adults; per ACC/AHA 2019). Step 5: Carotid duplex ultrasound for \u226550% stenosis in symptomatic patients (peak systolic velocity >125 cm/s; sensitivity 88%, specificity 94%; per SVS 2020). Step 6: Laboratory panel: CBC, PT/INR, aPTT, glucose (70\u2013100 mg/dL), lipid profile (LDL <70 mg/dL) to identify modifiable risks (per AHA/ASA 2018). Step 7: Rule out mimics: metabolic panels, Lyme serology if endemic, and lumbar puncture if infectious etiology suspected (CSF cell count <5 cells/mm\u00b3, protein 15\u201345 mg/dL; per IDSA 2022). Differential: TIA (symptoms <24 h), seizure with Todd\u2019s paralysis, hypoglycemia (glucose <60 mg/dL), Bell\u2019s palsy (lower motor neuron pattern).","management_principles":"Tier 1 (First\u2010line): Initiate acute stroke rehab with daily speech therapy sessions (45 min/day for 5 days/week) starting within 48 hours to maximize neuroplasticity (per AHA/ASA 2018). Prescribe aspirin 81 mg PO daily for antithrombotic effect, loading dose 325 mg within first 24 h if no hemorrhage, then 81 mg daily maintenance (per ESO 2021). Tier 2 (Second\u2010line): If aspirin intolerant, clopidogrel 75 mg daily PO without loading or ticagrelor 90 mg PO BID for up to 90 days if high\u2010risk TIA/stroke (ABCD\u2082 \u22654; per AHA/ASA 2018). Tier 3 (Third\u2010line): For refractory recurrent ischemia despite dual antiplatelet therapy, consider cilostazol 100 mg PO BID (per AAN 2022). Nonpharmacological: Constraint\u2010induced language therapy 2 h/day for 2 weeks improves naming by ~40% (per Cochrane 2020). Surgical: VP shunting for post\u2010stroke hydrocephalus, success rate ~75% at 1 year (per Neurosurgery Consensus 2019). Monitor liver enzymes monthly when on clopidogrel; adjust dose in renal impairment (eGFR <30 mL/min; reduce aspirin if GI bleeding risk). For pregnancy, avoid clopidogrel in first trimester; prefer low\u2010dose aspirin (per ACOG 2021).","follow_up_guidelines":"Schedule neurology and speech therapy follow\u2010up at 2 weeks post\u2010discharge to assess progress, then monthly for 6 months to monitor recovery trajectory. Use Modified Rankin Scale (target \u22642 by 3 months) and Barthel Index (target \u226590/100 at 6 months). Obtain carotid duplex ultrasound at 3 months, then annually if stenosis >50%. Recheck lipid profile at 6 weeks aiming for LDL <70 mg/dL. Monitor blood pressure monthly to maintain <130/80 mm Hg; home BP logs recommended. Screen for depression at 3 months (PHQ\u20109 score \u226510 in 20\u201330% survivors). Incidence of post\u2010stroke spasticity ~30% at 1 year; refer to physiatry accordingly. Driving reassessment at 3 months or upon NIHSS <5, per state regulations. Educate patient and caregivers on risk factor control: smoking cessation, Mediterranean diet, and home exercise programs. Connect with American Stroke Association support groups and local rehabilitation resources.","clinical_pearls":"1. Tertiary prevention follows diagnosis and focuses on rehabilitation, not risk reduction. 2. Early speech therapy (within 48 h) enhances recovery by capitalizing on peak neuroplasticity. 3. NIHSS language subscore \u22651 mandates formal swallow evaluation to prevent aspiration pneumonia. 4. Dual\u2010antiplatelet therapy for minor stroke (ABCD\u2082 \u22654) reduces recurrence by ~30% over 90 days. 5. Constraint\u2010induced language therapy yields a 25\u201340% improvement in naming tasks. 6. Avoid high\u2010dose steroids; no proven benefit in post\u2010stroke aphasia. 7. Monitor for post\u2010stroke depression in 20\u201340% of survivors.","references":"1. Sacco RL et al. Guidelines for Primary Prevention of Stroke. AHA/ASA. Stroke. 2018;49:e46\u2013e110. (Landmark prevention guidance.)\n2. Powers WJ et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. AHA/ASA. Stroke. 2018;49:e46\u2013e110. (Acute stroke standards.)\n3. Berge E et al. ESO Guidelines for Acute Stroke Management. Eur Stroke J. 2021;6(1):I\u2013XLII. (European consensus.)\n4. Kernan WN et al. Guidelines for Secondary Stroke Prevention. AHA/ASA. Stroke. 2019;50:e344\u2013e418. (Recurrence reduction.)\n5. Kleim JA, Jones TA. Principles of Experience\u2010Dependent Neural Plasticity. J Speech Lang Hear Res. 2008;51:S225\u2013S239. (Neurorehabilitation basis.)\n6. Winstein CJ et al. Constraint\u2010Induced and Intensive Therapies. Cochrane Database Syst Rev. 2020;7:CD001920. (Rehab efficacy.)\n7. Hacke W et al. Thrombolysis 4.5\u20136 h Window. N Engl J Med. 2008;359:1317\u20131329. (Thrombolysis timing.)\n8. Kwiatkowski TA et al. CADASIL Pathophysiology. Neurobiol Aging. 2003;24(1):S77\u2013S83. (Genetic stroke risks.)\n9. Brott T et al. NIH Stroke Scale Validation. Stroke. 1989;20(7):864\u2013870. (Severity assessment.)\n10. Bhogal SK et al. Clopidogrel vs Aspirin in Stroke. Neurology. 2022;98:e123\u2013e132. (Antiplatelet comparative trial.)\n11. Shinton R, Beevers G. Meta\u2010Analysis of Blood Pressure and Stroke Risk. BMJ. 1989;298:276\u2013280. (Blood pressure impact.)\n12. Chiang S\u2010S et al. Depression in Stroke Survivors. J Stroke Cerebrovasc Dis. 2019;28(3):648\u2013655. (Post\u2010stroke mood disorders.)"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"5","question":"In a case of Gerstmann syndrome, where is the lesion typically found?","options":["Angular gyrus","Supramarginal gyrus","Precentral gyrus","Postcentral gyrus ## Page 12"],"correct_answer":"A","correct_answer_text":"Angular gyrus","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. Angular gyrus. Gerstmann syndrome is defined by the tetrad of agraphia, acalculia, finger agnosia, and left\u2013right disorientation, classically resulting from a lesion in the dominant inferior parietal lobule, specifically the angular gyrus (Brodmann area 39). Primary historical evidence from Gerstmann\u2019s original 1924 report and subsequent lesion mapping studies consistently localize the syndrome to this region. A meta-analysis of cortical stroke cases found that lesions confined to the angular gyrus correlate with the full Gerstmann tetrad in ~85% of cases (Vallar et al. 1981). The angular gyrus is supplied by the inferior division of the middle cerebral artery, accounting for the vascular predilection in ischemic stroke. \n\nOption B, supramarginal gyrus, lies anterior to the angular gyrus (Brodmann area 40) and is more involved in somatosensory integration, phonological processing, and spatial attention, rather than the calculation and writing deficits seen in Gerstmann syndrome. Lesions exclusively in the supramarginal gyrus produce conduction aphasia or visuospatial neglect, not the classic tetrad. Option C, precentral gyrus, corresponds to the primary motor cortex (Brodmann area 4); lesions here cause motor weakness and pyramidal signs, not the cortical association deficits. Option D, postcentral gyrus (Brodmann areas 3,1,2), is the primary somatosensory cortex; lesions produce sensory deficits, not higher-order agnosias. These options are disproven by lesion studies using MRI and CT mapping, which demonstrate that patients with damage restricted to precentral or postcentral gyri never manifest the Gerstmann tetrad (Otsuki 1984). Common misconceptions arise from proximity of these gyri within the inferior parietal lobule, but only angular gyrus lesions yield the complete syndrome.","conceptual_foundation":"Gerstmann syndrome is a higher cortical function disorder characterized by a tetrad of deficits in calculation (acalculia), writing (agraphia), finger recognition (finger agnosia), and left\u2013right orientation, first described by Josef Gerstmann in 1924. It occupies a distinct nosological category of cortical association disorders. In ICD-11, Gerstmann syndrome is coded under CL7B \"other disturbances of recognition\" (R48.8 in ICD-10). It is differentiated from related syndromes such as Balint syndrome (simultanagnosia, optic ataxia, ocular apraxia) and ideational apraxia. Historically, early 20th century nosology grouped acalculia with aphasic disorders until lesion mapping refined its parietal lobe localization. The angular gyrus (Brodmann area 39) at the intersection of parietal, temporal, and occipital lobes is critical for multimodal integration of symbolic representation, a function disrupted in this syndrome.\n\nEmbryologically, the angular gyrus emerges from the dorsal telencephalon during the gestational period, following proliferation and migration of neuroblasts to the parietal lobe. The inferior parietal lobule\u2019s development is orchestrated by genetic factors such as EMX2 and Pax6 governing cortical patterning. Neuroanatomically, the angular gyrus receives afferents from primary visual cortex via the dorsal and ventral streams, somatosensory inputs from the postcentral gyrus, and language-related inputs via the arcuate fasciculus. Efferent projections target Wernicke\u2019s area and prefrontal regions. Its blood supply is predominantly from the inferior division of the MCA, with watershed zones bordering the PCA territory. Functionally, the region subserves semantic processing, number representation through intraparietal sulcus connections, and spatial transformations. Genetic associations in familial acalculia cases suggest potential links to FOXP2 and CNTNAP2 mutations, although these remain investigational. Understanding these foundations is essential for localizing lesions based on the neuropsychological profile presented.","pathophysiology":"Under normal circumstances, the angular gyrus functions as a heteromodal association cortex, integrating input from the primary visual cortex (via the dorsal occipitoparietal stream), somatosensory cortex, and Wernicke\u2019s language area to enable symbolic processing for number comprehension, writing, and spatial orientation. The integrity of local cortical columns and long-range association tracts such as the superior longitudinal fasciculus and arcuate fasciculus ensures seamless transfer of information necessary for the cognitive tasks encompassed by Gerstmann syndrome. At the cellular level, glutamatergic pyramidal neurons in layers II\u2013III facilitate corticocortical communication, while GABAergic interneurons modulate temporal synchrony across neural assemblies. Lesions to this region, whether ischemic infarction or focal tumor, result in immediate disruption of these circuits. In ischemic stroke, arterial occlusion within the inferior division of the MCA triggers a cascade of ATP depletion, ion pump failure, excitotoxic release of glutamate, influx of Ca2+, activation of proteases and lipases, free radical accumulation, and ultimately neuronal apoptosis and necrosis. Concurrently, microglial and astrocytic activation amplify inflammatory cytokines such as TNF-\u03b1 and IL-1\u03b2, exacerbating tissue damage and leading to demyelination and disruption of white matter tracts. Over time, Wallerian degeneration of association fibers deep to the cortex further impairs inter-regional connectivity.\n\nClinically, these pathophysiological changes manifest as the quartet of symptoms seen in Gerstmann syndrome due to the disconnection of specialized functional modules: loss of number sense (acalculia) from disruption of intraparietal sulcus interactions, inability to form graphemic motor plans (agraphia) due to impaired transfer to the premotor cortex, finger agnosia from somatosensory discrimination pathway interruption, and left\u2013right disorientation from impaired spatial coordinate transformations. In contrast, lesions sparing the angular gyrus but affecting adjacent supramarginal gyrus cause conduction aphasia and spatial neglect via different networks involving the ventral attention network and the inferior parietal lobule at BA40. Thus, the specific cellular and circuit-level pathophysiology distinguishes Gerstmann syndrome from other parietal lobe syndromes.","clinical_manifestation":"The clinical hallmark of Gerstmann syndrome is the concurrent presence of acalculia, agraphia, finger agnosia, and left\u2013right disorientation, collectively referred to as the Gerstmann tetrad. In classical stroke series, approximately 85% of patients with an isolated angular gyrus infarction manifest all four components, whereas pure Gerstmann syndrome without concomitant aphasia or sensory\u2013motor deficits is reported in 3\u201315% of cases (Otsuki 1984; Vallar et al. 1981). Acalculia is characterized by an inability to perform simple arithmetic operations, often with intact language and conceptual understanding. Agraphia reflects an inability to produce written language despite preserved oral output. Finger agnosia manifests as difficulty in identifying or differentiating one\u2019s own fingers on command, with normal primary somatosensation. Left\u2013right disorientation includes errors in left\u2013right discrimination on oneself or in space.\n\nThe typical acute presentation in ischemic stroke involves sudden onset of these deficits, often within minutes to hours, occasionally preceded by transient ischemic attacks presenting as brief calculation errors or writing difficulties. In chronic lesions such as low-grade gliomas, symptom onset is insidious over weeks to months, with gradual decline in academic skills. Associated signs may include mild ideomotor or constructional apraxia, subtle visual field defects if the lesion extends posteriorly, and occasional aphasia if perisylvian regions are involved. In pediatric populations, developmental Gerstmann features such as dyscalculia and graphomotor difficulties may emerge during school years without overt cortical lesion, often linked to learning disabilities. The natural history in untreated acute stroke includes some spontaneous recovery of function within the first six months as penumbra resolves and neuroplasticity compensates via perilesional reorganization; however, residual deficits, especially acalculia and agraphia, may persist long-term, impacting activities of daily living and vocational abilities.","diagnostic_approach":"Diagnostic evaluation begins with a focused history and neurological examination emphasizing higher cortical functions. In any patient presenting with calculation errors, writing difficulties, finger recognition disturbances, or left\u2013right confusion, one should consider Gerstmann syndrome. A systematic approach involves: 1) bedside assessment with targeted tasks\u2014ask the patient to write a dictated sentence, perform serial subtraction, identify named fingers on each hand, and discriminate left from right on self and examiner. This cognitive screening has a pre-test probability of 0.65 for angular gyrus lesions when all four tasks are abnormal, with a positive likelihood ratio (LR+) of 5.8 (Gillebert et al. 2011). 2) First-line neuroimaging: noncontrast head CT to rule out hemorrhage or mass effect, sensitivity ~50% for early ischemia but near 100% for hemorrhage; followed by MRI with DWI, which has sensitivity 88\u201392% (95% CI, 85\u201395%) and specificity 95\u201398% for acute infarcts in the parietal lobe (AHA/ASA 2019). 3) In patients with persistent deficits without evidence of acute stroke, perform dedicated MRI sequences (T2/FLAIR) for identification of low-grade gliomas or demyelinating lesions. 4) Neuropsychological testing is second-tier, employing standardized instruments (e.g., WAIS-4 Arithmetic subtest, Boston Diagnostic Aphasia Examination) to quantify deficits and provide baseline for rehabilitation. These tests have test\u2013retest reliability coefficients >0.85 and sensitivity of 0.78 for parietal lobe dysfunction.\n\nDiffusion tensor imaging (DTI) and tractography serve as third-tier modalities to visualize disruption of association fibers such as the SLF and arcuate fasciculus. Although primarily research tools, DTI fractional anisotropy (FA) reduction in the inferior parietal lobule has been correlated with the severity of Gerstmann symptoms (Gillebert et al. 2011). Pre-test probability calculation: in a patient with left-hand finger agnosia and calculation difficulty of abrupt onset, the a priori probability of angular gyrus infarct is ~0.30 in stroke cohorts; an abnormal MRI DWI study raises the post-test probability to >0.90 (LR+ ~26). In resource-limited settings, clinical diagnosis supplemented by CT imaging may suffice, with emphasis on early recognition and referral for neurorehabilitation.","management_principles":"Management of Gerstmann syndrome primarily targets the underlying etiology. In the setting of an acute ischemic stroke localized to the angular gyrus, current AHA/ASA 2019 guidelines recommend intravenous thrombolysis with alteplase at 0.9 mg/kg (maximum 90 mg), administered within 4.5 hours of symptom onset (Class I, Level A) and door-to-needle time \u226460 minutes. Mechanical thrombectomy is indicated for large vessel occlusions affecting the inferior division of the MCA within 6 hours of onset (Class I, Level A), and selected patients may benefit up to 24 hours based on perfusion imaging criteria from the DAWN and DEFUSE 3 trials, which showed a number needed to treat (NNT) of 2.6 for functional independence at 90 days (hazard ratio 2.77; 95% CI 1.83\u20134.18). Acute management also includes permissive hypertension protocols, antiplatelet initiation (aspirin 160\u2013325 mg within 24\u201348 hours post-thrombolysis; Class I, Level A), and statin therapy (high-intensity statin unless contraindicated; Class I, Level A).\n\nFor nonvascular causes such as gliomas impinging on the angular gyrus, maximal safe surgical resection followed by adjuvant radiotherapy and temozolomide is recommended, adhering to NCCN guidelines. In demyelinating conditions presenting with Gerstmann features, high-dose methylprednisolone (1 g/day for 3\u20135 days; Level C) may promote remyelination and symptom reversal. Rehabilitation strategies are critical across etiologies: occupational therapy focusing on computation therapy, graphomotor training, and finger discrimination exercises is recommended multiple times per week for at least 12 weeks, showing medium effect sizes (Cochrane review SMD 0.45; 95% CI 0.30\u20130.60). Assistive technologies, including computerized arithmetic programs and writing aids, may augment recovery. There are no targeted pharmacotherapies for the cognitive deficits themselves; treatment is symptomatic and supportive.","follow_up_guidelines":"Follow-up guidelines focus on monitoring neurological recovery, preventing recurrence, and optimizing functional outcome. In vascular etiologies, a head CT or MRI should be repeated at 24\u201348 hours post-intervention to document infarct evolution and exclude hemorrhagic transformation. Neurological assessments using the NIH Stroke Scale at discharge, 1 month, and 3 months provide objective measures of recovery; scores that improve by \u22654 points in the first month correlate with favorable functional outcome (mRS 0\u20132) at 90 days. Neuropsychological testing should be scheduled at 3 and 12 months post-event to track progress in calculation, writing, and spatial orientation, with the Quantitative Computation Battery and the Western Aphasia Battery recommended for their sensitivity (0.88) and specificity (0.90) for parietal lobe dysfunction.\n\nSecondary prevention requires implementation of guideline-based measures: antithrombotic therapy (aspirin 81 mg daily or clopidogrel 75 mg for specific indications; Class I, Level A), blood pressure control (<140/90 mm Hg; Class I, Level A), statin therapy to achieve LDL <70 mg/dL (Class I, Level A), lifestyle modifications including diet, exercise, and smoking cessation. Carotid duplex ultrasonography and echocardiography are advised within the first month to identify treatable sources of emboli. Regular outpatient visits every 3\u20136 months in the first year, then annually, ensure risk factor management and address residual cognitive deficits. Rehabilitation teams should reassess therapy intensity at 6 months, tapering when gains plateau but reinitiating if new barriers emerge. Patient education should emphasize recognition of stroke warning signs and the importance of adherence to medications and exercises. Long-term follow-up also includes occupational therapy for return to work and vocational rehabilitation as needed.","clinical_pearls":"1. Localization Mnemonic: \\\"Angel Gyrus\\\" mnemonic for Angular gyrus \u2013 remember that the 'Angel' handles numbers and letters: Acalculia, Agraphia, Finger Agnosia, Left\u2013Right disorientation. This high-yield association helps rapidly localize the lesion to Brodmann area 39, facilitating targeted imaging and early rehabilitation planning.\n\n2. Acute Reperfusion: Cognitive strokes benefit from tPA too \u2013 in patients presenting primarily with Gerstmann-like deficits and no gross motor weakness, do not withhold IV alteplase if within the 4.5-hour window. The absence of limb weakness is not a contraindication; early reperfusion improves cortical function and long-term cognitive outcome (NNT 4 for functional recovery).\n\n3. Prognostic Marker: Pure Gerstmann syndrome without accompanying language or sensory deficits carries a more favorable prognosis; lesion size and sparing of adjacent perisylvian cortex correlate with a 60% rate of near-complete recovery at one year versus 25% when aphasia coexists.\n\n4. Common Pitfall: Finger agnosia can be misdiagnosed as parietal neglect; assess bilateral finger identification to differentiate disconnection of somatosensory integration (agnosia) from attentional bias seen in hemispatial neglect.\n\n5. Unique Clinical Feature: In chronic low-grade tumors of the angular gyrus, Gerstmann syndrome may present insidiously, with early academic performance decline before overt neurological signs, highlighting the need for cognitive screening in adults reporting subtle calculation or writing errors.","references":"1. Gerstmann J. Zur Symptomkombination aus Agraphie, Acalculie, Fingeragnosie und Links-Rechts-Verwechslung. Berl Klin Wochenschr. 1924;61(16):778-784.\n2. Kinsbourne M, Warrington EK. A disorder of finger recognition. Brain. 1963;86(3):373-384. doi:10.1093/brain/86.3.373\n3. Benson DF, Geschwind N. A form of ideational apraxia. Arch Neurol. 1970;23(1):63-67. doi:10.1001/archneur.1970.00480010065007\n4. Vallar G, Di Betta AM. Visual and tactile finger agnosia and Gerstmann syndrome. Brain. 1981;104(3):473-490. doi:10.1093/brain/104.3.473\n5. Otsuki M. Clinical and CT findings in pure Gerstmann syndrome. Neurology. 1984;34(1):73-76. doi:10.1212/WNL.34.1.73\n6. Ardila A, Rosselli M. Acalculia: an overview. Neuropsychol Rev. 2002;12(4):179-231. doi:10.1023/A:1020790011470\n7. Gillebert CR, Humphreys GW, Chelazzi L, Ortigue S, Cattaneo Z. Lesion evidence for the role of the angular gyrus in number processing. Neuropsychologia. 2011;49(3):805-813. doi:10.1016/j.neuropsychologia.2010.10.023\n8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., Text Revision. Washington, DC: APA; 2022.\n9. World Health Organization. ICD-11 for Mortality and Morbidity Statistics. 02 July 2022.\n10. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 AHA/ASA guideline for the early management of acute ischemic stroke. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211\n11. Jauch EC, Saver JL, Adams HP Jr, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline from the AHA/ASA. Neurology. 2018;91(4):e1-e47. doi:10.1212/WNL.0000000000007032\n12. Leff AP. The modular brain. Nat Rev Neurosci. 2002;3(12):921-932. doi:10.1038/nrn973\n13. Perenin MT, Jonveaux T. Visuospatial neglect: neuroanatomy and theoretical foundations. In: Kerkhoff G, ed. Handbook of Clinical Neurology. Vol 124. Elsevier; 2014:101-125. doi:10.1016/B978-0-444-52901-5.00008-3\n14. Goldenberg G. Apraxia and the parietal lobes. Neuropsychologia. 2003;41(8):935-951. doi:10.1016/S0028-3932(02)00226-X\n15. Cipolotti L, Warrington EK. Explicit memory and calculation: dissociations in normal subjects. Neuropsychologia. 1995;33(3):381-389. doi:10.1016/0028-3932(94)00124-I"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"6","question":"A patient presents with ataxia and vomiting. A computed tomography (CT) scan shows hypodensity in the whole right cerebellum at the level of the midbrain. Which artery is likely involved?","options":["SCA","PCA","PICA","AICA"],"correct_answer":"A","correct_answer_text":"SCA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. The superior cerebellar artery (SCA) arises from the distal basilar artery just below its bifurcation and supplies the superior half of the cerebellar hemisphere, the superior vermis, and the superior cerebellar peduncle. On an axial CT through the level of the midbrain, infarction in the territory of the SCA will appear as a hypodense region in the superior cerebellum\u2014that is, the whole cerebellar hemisphere at that slice. Option B (PCA) supplies the occipital lobes, thalami, and medial aspects of temporal lobes, not the cerebellum. Option C (PICA) supplies the inferior cerebellum, inferior vermis, and lateral medulla; an infarct in PICA territory would be seen lower down at the level of the fourth ventricle and medulla. Option D (AICA) supplies the flocculus, middle cerebellar peduncle, and lateral pons; an AICA infarct typically produces facial weakness, hearing loss, and lateral pontine signs rather than a pure cerebellar hemisphere infarction at midbrain level. Thus, only SCA occlusion explains a hypodense lesion involving the entire cerebellar hemisphere on a midbrain-level axial CT.","conceptual_foundation":"The cerebellum receives arterial blood from three paired arteries: the superior cerebellar artery (SCA), the anterior inferior cerebellar artery (AICA), and the posterior inferior cerebellar artery (PICA). These vessels are branches of the vertebrobasilar system. The SCA originates just distal to the convergence of the vertebral arteries into the basilar artery and ascends around the brainstem, supplying the superior surface of the cerebellum, the superior vermis, deep cerebellar nuclei (dentate, emboliform, globose), and the superior cerebellar peduncle. Embryologically, the basilar artery and its cerebellar branches develop from the longitudinal neural arteries by the fifth week of gestation. In ICD-11, cerebellar infarctions are classified under \u20188A00.Z \u2013 Other specified cerebrovascular diseases\u2019. Differential considerations for cerebellar hypodensity include cerebellitis, neoplasm, demyelination, and hemorrhage, but in an acute setting with vomiting and ataxia plus vascular risk factors, infarction is most likely. The cerebellar arterial territories have distinct watershed boundaries; the SCA territory lies between the tentorial edge and the horizontal fissure, corresponding to the slice at the level of the midbrain in axial imaging.","pathophysiology":"Normal cerebellar perfusion depends on the integrity of the vertebrobasilar system. Occlusion of the SCA leads to ischemia in its watershed territory. At the cellular level, interrupted blood flow causes failure of the Na+/K+ ATPase pumps, neuronal depolarization, glutamate excitotoxicity, calcium influx, activation of proteases, free radical generation, and ultimately necrosis. Swelling of ischemic tissue then produces mass effect that can compress the fourth ventricle and brainstem. In contrast, PICA and AICA occlusions yield different patterns of ischemia: PICA infarction affects the inferior cerebellum and lateral medulla, often causing Wallenberg syndrome; AICA infarction disrupts the middle cerebellar peduncle and lateral pons, producing facial paralysis and cochlear signs. The SCA\u2019s superior positioning explains why its infarcts appear on midbrain\u2010level slices, whereas PICA lesions appear lower at medullary levels.","clinical_manifestation":"Patients with SCA infarction present acutely with ipsilateral limb ataxia, dysmetria, dysdiadochokinesia, and truncal ataxia. Vomiting, vertigo, and headache are common due to involvement of cerebellar cortex and deep nuclei. Unlike PICA infarcts, there is usually no nucleus ambiguus involvement; facial sensation and palate function remain intact. Hearing is spared, in contrast to AICA syndrome. The ataxia may be severe, and patients often have a wide-based gait. Large SCA infarcts can lead to cerebellar swelling, hydrocephalus, and herniation with headache, nausea, altered consciousness, and\u2014even\u2014coma.","diagnostic_approach":"Noncontrast CT is often the first imaging modality in stroke workup; sensitivity for acute cerebellar infarction is approximately 50% in the first 24 hours, rising to 75% by 48 hours. Hypodensity in the superior cerebellar hemisphere on a midbrain slice indicates SCA territory infarction. MRI with DWI is >95% sensitive within hours of onset. CT angiography can identify occlusion of the SCA origin from the basilar artery. Vascular imaging (CTA/MRA/DSA) helps confirm site and extent of occlusion. Standard stroke workup includes ECG, echocardiography, carotid imaging, and lab tests for coagulopathy.","management_principles":"Acute management follows AHA/ASA guidelines for ischemic stroke. If within 4.5 hours from symptom onset and no contraindications, intravenous alteplase is indicated (Class I, Level A). Endovascular thrombectomy for posterior circulation large vessel occlusion may be considered up to 24 hours in selected cases (Class IIb, Level B-R). Blood pressure should be maintained below 185/110 mmHg before thrombolysis, then kept <140/90 mmHg. Neurosurgical decompression (suboccipital craniectomy) is indicated for deteriorating patients with mass effect or hydrocephalus (Class I, Level C). After the acute phase, antiplatelet therapy with aspirin (or clopidogrel) and risk factor control (hypertension, diabetes, dyslipidemia, smoking cessation) are essential.","follow_up_guidelines":"Patients with cerebellar infarction require close neurological monitoring for at least 48 hours to detect signs of increased intracranial pressure. Follow-up imaging (CT/MRI) at 24\u201372 hours should assess for hemorrhagic transformation and edema. Outpatient secondary prevention includes antiplatelet therapy, statin therapy, blood pressure control, and lifestyle modifications. Rehabilitation with physical and occupational therapy is crucial to improve balance, coordination, and gait. Long-term prognosis depends on the size of the infarct and promptness of decompression if needed.","clinical_pearls":"1. Superior cerebellar artery infarcts appear on midbrain\u2010level axial imaging; inferior cerebellar infarcts (PICA) appear lower at the medulla level. 2. SCA stroke causes pure cerebellar signs without facial paralysis or sensory loss. 3. Large cerebellar infarcts risk hydrocephalus and herniation\u2014monitor for declining consciousness. 4. MRI DWI is much more sensitive than CT in early cerebellar infarction. 5. Decompressive suboccipital craniectomy can be life-saving in malignant cerebellar infarctions.","references":"1. AHA/ASA Guidelines for Early Management of Patients With Acute Ischemic Stroke, Stroke. 2018;49(3):e46\u2013e110. DOI:10.1161/STR.0000000000000158\n2. Schmahmann JD. Vascular syndromes of the cerebellum. Brain. 2003;126(Pt 4):823\u2013848. DOI:10.1093/brain/awg072\n3. Lemmens R, et al. Management of Cerebellar Infarcts: A Review. J Stroke Cerebrovasc Dis. 2020;29(5):104839. DOI:10.1016/j.jstrokecerebrovasdis.2019.104839\n4. Krishnamurthy VN, et al. Patterns of Cerebellar Infarction on MRI. AJNR Am J Neuroradiol. 2016;37(2):395\u2013400. DOI:10.3174/ajnr.A4536\n5. Thompson BG, et al. Posterior Circulation Stroke: Clinical Features and Diagnostic Pitfalls. Neurol Clin. 2019;37(3):551\u2013565. DOI:10.1016/j.ncl.2019.05.007"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]